NASDAQ:GLPGGALAPAGOS NV/S Stock Price, Forecast & News

GALAPAGOS NV/S's stock was trading at $186.06 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, GLPG shares have increased by 9.0% and is now trading at $202.78. View which stocks have been most impacted by Coronavirus.

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GALAPAGOS NV/S in the last year. There are currently 2 sell ratings, 7 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for GALAPAGOS NV/S.

GALAPAGOS NV/S is scheduled to release its next quarterly earnings announcement on Thursday, July 23rd 2020. View our earnings forecast for GALAPAGOS NV/S.

GALAPAGOS NV/S (NASDAQ:GLPG) posted its quarterly earnings data on Thursday, May, 7th. The biotechnology company reported ($0.86) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.95) by $0.09. The biotechnology company had revenue of $117.93 million for the quarter, compared to analysts' expectations of $121.39 million. GALAPAGOS NV/S had a net margin of 15.42% and a return on equity of 12.45%. View GALAPAGOS NV/S's earnings history.

16 equities research analysts have issued 1-year price targets for GALAPAGOS NV/S's shares. Their forecasts range from $155.00 to $298.00. On average, they anticipate GALAPAGOS NV/S's share price to reach $229.00 in the next year. This suggests a possible upside of 12.9% from the stock's current price. View analysts' price targets for GALAPAGOS NV/S.

News articles about GLPG stock have been trending positive this week, according to InfoTrie Sentiment. The research group identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. GALAPAGOS NV/S earned a news impact score of 2.8 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the next few days. View the latest news aboutGALAPAGOS NV/S.

Some companies that are related to GALAPAGOS NV/S include ASTELLAS PHARMA/ADR (ALPMY), Alexion Pharmaceuticals (ALXN), Shiseido (SSDOY), Takeda Pharmaceutical (TKPYY), Genmab A/S (GMAB), UCB (UCBJF), Genmab A/S (GNMSF), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), Merck KGaA (MKGAF), Teva Pharmaceutical Industries (TEVA), GRIFOLS S A/S (GRFS), Beigene (BGNE), Catalent (CTLT) and Sarepta Therapeutics (SRPT). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other GALAPAGOS NV/S investors own include Gilead Sciences (GILD), CELYAD SA/ADR (CYAD), Intercept Pharmaceuticals (ICPT), argenx (ARGX), NVIDIA (NVDA), AbbVie (ABBV), Pharming Group (PHGUF), Trade Desk (TTD), Biogen (BIIB) and Collegium Pharmaceutical (COLL).

(GLPG) raised $161 million in an IPO on Thursday, May 14th 2015. The company issued 3,800,000 shares at $42.43 per share. Morgan Stanley, Credit Suisse and Cowen and Company served as the underwriters for the IPO and Nomura and Bryan, Garnier were co-managers.

GALAPAGOS NV/S trades on the NASDAQ under the ticker symbol "GLPG."

GALAPAGOS NV/S's stock is owned by a variety of retail and institutional investors. Top institutional investors include Sands Capital Management LLC (3.44%), Federated Hermes Inc. (2.17%), BlackRock Inc. (0.49%), Bessemer Group Inc. (0.36%), Wellington Management Group LLP (0.20%) and Morgan Stanley (0.19%).

GLPG stock was sold by a variety of institutional investors in the last quarter, including Sands Capital Management LLC, Wellington Management Group LLP, Federated Hermes Inc., Jane Street Group LLC, Bessemer Group Inc., Public Employees Retirement Association of Colorado, Wealth Quarterback LLC, and Peregrine Capital Management LLC.

GLPG stock was purchased by a variety of institutional investors in the last quarter, including Citigroup Inc., Morgan Stanley, Morgan Stanley, BlackRock Inc., Acadian Asset Management LLC, United Capital Financial Advisers LLC, Envestnet Asset Management Inc., and Parametric Portfolio Associates LLC.

Shares of GLPG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of GLPG stock can currently be purchased for approximately $202.78.

GALAPAGOS NV/S has a market capitalization of $13.14 billion and generates $1.00 billion in revenue each year. The biotechnology company earns $167.83 million in net income (profit) each year or $5.46 on an earnings per share basis. GALAPAGOS NV/S employs 1,003 workers across the globe.

The official website for GALAPAGOS NV/S is www.glpg.com.

GALAPAGOS NV/S's mailing address is GEN DE WITTELAAN L11 A3, MECHELEN C9, 2800. The biotechnology company can be reached via phone at 321-534-2900 or via email at [email protected]